Certara Inc.

Issued on behalf of Aleen Inc.

VANCOUVER, BC, Dec. 12, 2025 /CNW/ -- Equity Insider News Commentary – Major pharmaceutical companies are cutting drug discovery timelines by 30% or more through AI models that predict molecular behavior before researchers invest months in testing, marking a fundamental shift from traditional trial-and-error approaches to computational creation of biological solutions^[1]. The generative AI healthcare market is projected to surge from $2.64B in 2025 to $39.70B by 2034, reflecting the technology's expansion from simple data analysis to active creation and interpretation of therapeutic compounds^[2]. This Platform-First revolution is extending rapidly into consumer wellness, where companies deploy similar AI logic to help individuals decode the complex patterns of their own daily health. These developments position Amazon.com, Inc. (NASDAQ: AMZN) company, Absci Corporation (NASDAQ: ABSI), Certara, Inc. (NASDAQ: CERT), and SOPHiA GENETICS SA (NASDAQ: SOPH as leaders capturing the transformation. Alongside these developments in the broader industry, Aleen Inc. (CSE: ALEN-U) is advancing within the digital wellness segment with non-medical analytics helping individuals understand their everyday well-being patterns.

AI healthcare investment has already reached $10.7B in 2025, exceeding the entire 2024 total by 24% with nine months still remaining, as pharmaceutical companies race to compress development cycles that traditionally spanned more than a decade^[3]. The timing advantages compound as digital wellness platforms raised $52M to build autonomous laboratories this week alone, signaling accelerating momentum toward AI-driven creation systems that promise to redefine both therapeutic discovery and personal health analytics before competitors establish market dominance^[4].

Aleen Inc. (CSE: ALEN-U), a Canadian digital wellness company, recently emphasized its commitment to personal reflection and self-awareness rather than medical assessment. The company clarified that its Wellness AI platform focuses on helping users notice habits, reflect on daily experiences, and uncover individual patterns without providing medical diagnoses or clinical assessments.

"Our goal is to help people observe themselves with clarity," said Oleksandr Luzin, Director of Aleen Inc. "Wellness AI is not about diagnosis -- it is about reflection, insight, and discovering what your own patterns can teach you."

The company previously announced the development of a personal account system designed to redefine how individuals interact with their wellness data. The upcoming personal account will serve as an intuitive hub where users can seamlessly upload, manage, and visualize their non-medical well-being information.

"Our current focus is on understanding how an analytical tool can responsibly support everyday well-being -- while staying entirely outside the realm of diagnostic or medical functions," said Anastasiia Kalashnik, PR Specialist of Aleen Inc. "We are laying the groundwork for a feature that inspires awareness and self-reflection, not prescribes actions."

Based in Ontario, Aleen Inc. went public in June 2025 and has developed an AI platform designed to help users understand their inputs and wellness indicators. The company operates in a rapidly expanding market, with the global digital wellness sector currently valued at approximately $12.87 billion in 2025 and projected to grow to $45.65 billion by 2034, representing annual growth of 15.1%. With about 57% of consumers now using digital apps and wearable devices to monitor their well-being, Aleen is positioned to capture a portion of this expanding demand.

The Aleen AI system can be accessed in two ways. Users can visit the Aleen website for free wellness insights, which helps raise awareness and encourages active engagement with personal well-being. Businesses can integrate Aleen's technology via its API, allowing wellness apps and digital platforms to embed the AI-powered insights into their own services. The company generates revenue through its API offerings, available through a per-call option for businesses paying only for requests used, and a monthly subscription for consistent access.

Looking ahead to 2026, Aleen plans to launch the personal user accounts currently in development alongside the smart analytics features being tested. To fund these initiatives, Aleen is currently seeking between $20 million and $30 million in strategic investment, with plans to allocate 35% toward technology development, 30% toward sales and marketing efforts, and 20% for product expansion.

With 12,643,300 common shares currently issued and outstanding, Aleen Inc. continues to build its presence in the digital wellness space under the leadership of CEO Inna Aksman. The company emphasizes that its platform is designed for preliminary wellness insights only and is not intended to replace consultations with healthcare professionals.

CONTINUED… Read this and more news for Aleen Inc. at:  

https://equity-insider.com/2025/10/31/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/

Amazon Web Services (AWS), an Amazon.com, Inc. (NASDAQ: AMZN) company, announced that Proteintech, a global leader in antibody and life science solutions, has selected AWS as its preferred cloud provider and successfully built the industry's first AI antibody assistant called "Able" in just six months. Proteintech has migrated 85% of its workloads to AWS, leveraging the platform's compute, containers, database, and analytics services to reduce Able's launch cycle by 50% while cutting operational costs through elastic cloud computing resources.

"We are proud to support Proteintech in their mission to empower scientists with an intelligent AI research assistant that accelerates discovery and fuels innovation in life sciences," said Jared Saul, Chief Medical Officer, Commercial Healthcare and Life Sciences at AWS. "We're pleased to enable Proteintech with leading cloud services and generative AI technology to help scientists accelerate biomarker discovery, improve research efficiency, and drive breakthrough scientific discoveries in the field of life sciences."

Able provides researchers with precise product information and technical support through conversational interactions, sharing Proteintech's product data, experimental data, and scientific knowledge to enable faster experimental design.

Absci Corporation (NASDAQ: ABSI) has unveiled human ex vivo data showing its AI-designed antibody ABS-201 stimulates hair growth by regenerating the stem cell niche and preserving the CD34+ progenitor cell pool whose reduction defines androgenetic alopecia. Studies using organ-cultured human scalp skin demonstrated ABS-201 prolongs the anagen growth phase and facilitates reconversion of miniaturized vellus follicles into terminal hair follicles, with the model considered highly predictive of clinical response.

The company is advancing ABS-201 through its Phase 1/2a HEADLINE study for androgenetic alopecia, which affects approximately 80 million Americans, with interim data anticipated in the second half of 2026. In preclinical mouse models, ABS-201 demonstrated statistically significant superior hair regrowth compared to minoxidil, one of only two FDA-approved treatments, positioning the antibody as a potential disease-modifying therapeutic addressing root causes current treatments do not target.

Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, announced the launch of TFL Studio, the first cloud-native module of its Phoenix Cloud solution that uses AI to cut scientific workflow time by 50% for drug developers. The platform automates the creation of regulatory submission documents that are critical components of bringing new treatments to market, serving more than 2,400 biopharmaceutical companies across 70 countries.

"TFL Studio empowers scientists to create high-quality TFLs up to 50% faster, freeing them from the technical complexities of moving source data, coding, and manual formatting," said Martin Snyder, President of Certara Data Sciences. "This allows them to focus on science, derive insights more quickly, and ultimately accelerate critical decision-making."

A complementary AI module launching this quarter will leverage generative AI to transform data into draft reports in minutes rather than days, powered by CoAuthor, Certara's GenAI software for regulatory writing. The cloud-based platform aims to accelerate the drug development timeline by automating time-consuming documentation processes that traditionally slow down the path from discovery to patient access.

SOPHiA GENETICS (NASDAQ: SOPH) has announced a partnership with Element Biosciences at the Association for Molecular Pathology Annual Meeting that integrates the company's AI-powered SOPHiA DDM™ analytics platform with Element's AVITI24™ 5D multiomic and AVITI™ sequencing systems to deliver seamless end-to-end workflows for next-generation sequencing. The collaboration provides AVITI and AVITI24 users access to the full suite of SOPHiA DDM™ applications in oncology and rare disease, combining speed, scalability and flexibility to enable clinical researchers to transform NGS data into actionable insights within a single streamlined process.

"Integrating our universal platform with leading sequencing technologies such as the Element AVITI system allows healthcare organizations, regardless of size or geography, to adopt innovative, AI-driven technologies while keeping genomic research local," said Jurgi Camblong, CEO of SOPHiA GENETICS. "This partnership aligns with our shared goals of democratizing access to research that supports precision medicine globally, bringing data-driven decisions closer to home, and extending the reach of our respective technologies."

The technology-agnostic SOPHiA DDM™ platform leverages AI to compute, standardize and analyze healthcare data, enabling laboratories to process datasets of any size while retaining full control of their data and scaling efficiently as precision medicine adoption accelerates worldwide. Element Biosciences' AVITI24 5D Multiomic and AVITI systems are designed to make high-performance genomics accessible through their combination of accuracy, flexibility and cost efficiency, empowering laboratories to scale with confidence and accelerate research driving precision medicine globally.

Article Sources: https://equity-insider.com/2025/10/31/ai-engine-replaces-the-waiting-room-powering-the-660b-health-revolution/

CONTACT:

USA NEWS GROUP 

info@usanewsgroup.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Aleen Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Aleen Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. MIQ has not been paid for the mention of Amazon.com, Inc. nor do we own any shares of Amazon.com, Inc. MIQ has not been paid for the mention of Absci Corporation nor do we own any shares of Absci Corporation. MIQ has not been paid for the mention of Certara, Inc. nor do we own any shares of Certara, Inc. MIQ has not been paid for the mention of SOPHiA GENETICS SA nor do we own any shares of SOPHiA GENETICS SA. The owner/operator of MIQ own shares of Aleen Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Aleen Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. Aleen's solutions operate within the wellness domain and are not subject to FDA or Health Canada approval.

SOURCES:

1.   https://www.healthcare-brew.com/stories/2025/12/11/merck-nvidia-new-drug-discovery-model

2.   https://www.biospace.com/press-releases/generative-ai-in-healthcare-market-a-new-era-of-intelligent-personalized-and-predictive-care

3.   https://news.crunchbase.com/health-wellness-biotech/ai-healthcare-funding-rises-2025/

4.   https://www.bloomberg.com/news/articles/2025-12-11/medra-raises-52-million-to-speed-drug-discovery-with-ai-robots  

Logo - https://mma.prnewswire.com/media/2840019/5669355/Equity_Insider_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/ai-creation-engines-transform-biotech-as-wellness-tech-captures-growth-wave-302640247.html

Equity Insider News Commentary

Issued on behalf of Avant Technologies Inc.

VANCOUVER, BC, May 23, 2025 /PRNewswire/ -- Equity Insider News Commentary – A new report from Philips reveals a growing divide between doctors and patients when it comes to AI in healthcare. While 63% of surveyed healthcare professionals believe AI can help improve outcomes, only 48% of patients share that optimism. As researchers explore what's needed for successful AI adoption in healthcare, major players in tech and biotech are already moving ahead—recent updates have come from Avant Technologies, Inc. (OTCQB: AVAI), Renovaro Inc. (NASDAQ: RENB), Certara, Inc. (NASDAQ: CERT), CareCloud, Inc. (NASDAQ: CCLD), and Microsoft Corporation (NASDAQ: MSFT).

Analysts at MarketsandMarkets expect the AI healthcare sector to grow at a 38.6% CAGR, topping $110 billion by 2030. Accenture goes even further, estimating AI could inject another $461 billion in added value by 2035—amplifying impact across a global healthcare system already on track to surpass $2.26 trillion.

Avant Technologies, Inc. (OTCQB: AVAI), in partnership with Ainnova Tech, is positioning its Vision AI platform at the forefront of predictive healthcare. The company is in advanced discussions to acquire or exclusively license a patented early disease detection technology that could significantly enhance its diagnostic capabilities. If finalized, the deal would allow Vision AI to generate clinical insights even in the absence of a complete patient dataset—unlocking earlier intervention opportunities and supporting a more proactive model of care.

"Our purpose is to create the future of early disease detection in an accessible way, so that patients can get a preventive check-up anywhere, at a low cost, and easily," said Vinicio Vargas, CEO at Ainnova and member of the Board of Directors of the joint venture company, Ai-nova Acquisition Corp. (AAC), said of AAC's aim to continue to add to its portfolio. "We want to prevent patients with risk factors from developing other diseases that could have been avoided before they became a real problem. To this end, we are seeking to integrate new technologies into our portfolio within a single platform, both through our R&D efforts and through potential exclusive licenses or acquisitions."

The potential acquisition aligns with Avant and Ainnova's shared mission to deliver scalable, preventive health tools that merge retinal imaging, vital sign monitoring, and machine learning into one streamlined platform. Vision AI is already positioned as a next-generation diagnostic engine for chronic conditions like diabetes, cardiovascular disease, and kidney dysfunction. Now, the joint venture is pushing further—evaluating breakthrough technologies that could detect emerging health issues at a pre-symptomatic stage.

Recent platform updates saw four proprietary algorithms—trained on over 2.3 million real-world clinical cases—fully integrated into Vision AI. The addition of new IP from this proposed deal would mark a significant leap forward, enabling predictive models to extract meaningful signals from even limited patient data.

Avant and Ainnova view this initiative as part of a broader strategy to consolidate breakthrough tools that make early disease detection more scalable, mobile, and applicable across diverse healthcare settings. While a final agreement has yet to be announced, the companies have stated they will keep shareholders informed as developments progress.

In parallel, Avant has entered formal discussions to acquire Ainnova outright—building on their existing alignment under the Ai-nova Acquisition Corp. (AAC) structure. The timing is deliberate, coming just ahead of a planned FDA pre-submission meeting this July. A completed merger would unify operations, reduce internal complexity, and bolster the joint venture's regulatory readiness as it prepares for potential U.S. market entry.

"We believe bringing the two companies together will offer tremendous value for shareholders," said Vargas. "It will simplify the process of advancing our technology to market, and it will deliver value to our customers and partners as we promote our technology portfolio globally."

At the center of this initiative is Vision AI—a non-invasive screening platform that integrates retinal imaging, vital sign monitoring, and machine-learning models to flag early indicators of chronic disease. The system targets conditions such as diabetic retinopathy, cardiovascular issues, kidney and liver disorders, and type 2 diabetes. Operated under the AAC structure, the joint venture holds global rights to Vision AI, which has demonstrated over 90% sensitivity in early detection based on research cited by the NIH.

"This milestone reflects our two-tiered strategy, rapid deployment in low-regulation markets where Vision AI operates as a screening tool, and simultaneous progress toward FDA clearance for the U.S. market," said Vargas. "Entering the U.S. will unlock significant commercial potential, and early engagement with regulators ensures we do so with speed, credibility, and a validated product."

While many AI healthcare platforms remain stuck in pilot stages, Avant's Vision AI is already live across multiple Latin American markets—including Chile, Mexico, and Brazil—where it's actively being used in clinical settings. These real-world deployments are generating essential data on safety and efficacy, while also providing user feedback that guides ongoing system improvements.

To broaden its diagnostic reach, the Ai-nova joint venture recently integrated four additional algorithms into the platform. Each was trained on a dataset of more than 2.3 million clinical records, enhancing Vision AI's precision across a wider spectrum of chronic diseases. With active momentum abroad and U.S. regulatory discussions now underway, Avant's trajectory appears to be moving from early validation toward broader market penetration.

CONTINUED... Read this and more news for Avant Technologies at:

https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/ 

Renovaro Inc. (NASDAQ: RENB) has officially launched Augusta, a next-generation AI-powered platform targeting precision neurology. Designed for patient stratification, biomarker discovery, and accelerated drug development, Augusta integrates multiomics, contingent AI, phenoclustering, and in silico screening into one modular system.

"The Augusta platform is about validation," said David Weinstein, CEO of Renovaro Inc. "We're setting a new bar for how AI can be responsibly and effectively deployed in clinical and experimental settings."

The platform has already demonstrated early success in Parkinson's disease and epilepsy, with expansion plans underway for additional neurological conditions.

Certara, Inc. (NASDAQ: CERT) has launched its Non-Animal Navigator™ solution to help drug developers reduce reliance on animal testing, aligning with the FDA's Roadmap to Reducing Animal Testing in Preclinical Safety Studies.

"The FDA announcement and roadmap pave the way for more model-informed drug development approaches that are predictive, efficient, and ethical," said William F. Feehery, CEO of Certara Inc. "It is part of a growing industry adoption trend to use scientifically robust new approach methodologies (NAMs) like AI-enabled biosimulation to improve strategic decision-making and success rates at every phase of drug development."

The new offering combines strategic regulatory guidance with AI-enabled biosimulation, providing an ethical and efficient pathway through early-stage drug development. With adoption already underway, Certara's platform offers a future-ready model for companies advancing biologics, including monoclonal antibodies and ADCs.

CareCloud, Inc. (NASDAQ: CCLD) has been named Maxim Group's "Top Healthcare IT Pick for 2025," with analysts citing the company's AI-first strategy, strong financial performance, and discounted valuation as key drivers.

"AI is now deeply integrated into our operations—from documentation and revenue cycle management to patient engagement and analytics," said Hadi Chaudhry, Co-CEO of CareCloud Inc. "This is not an add-on, it is a foundational capability that is changing how healthcare is delivered and experienced."

The firm recently launched its AI Center of Excellence and introduced purpose-built tools like cirrusAI Notes and cirrusAI Voice to streamline clinical workflows and improve patient engagement. CareCloud plans to scale its AI team from 50 to 500 by year-end, deepening its role as a leader in applied healthcare AI.

Microsoft Corporation (NASDAQ: MSFT) has introduced its healthcare agent orchestrator—a multi-agent AI framework designed to support complex clinical workflows, such as tumor boards, by analyzing multimodal data across imaging, genomics, and electronic health records.

"The vision of the healthcare agent orchestrator is to rapidly surface, summarize, and take action on relevant multimodal medical information for each complex cancer case, so hours of review can become minutes," said Dr. Joshua Warner, Radiologist at UW Health and Assistant Professor of Radiology, UW School of Medicine and Public Health. "Collaborating with Microsoft allows us to explore the value of these models for tumor boards and beyond."

Now available through Azure AI Foundry, the system enables clinicians and developers to coordinate specialized AI agents directly within Microsoft Teams and Office tools, streamlining hours of expert analysis into minutes. Leading institutions like Stanford, Johns Hopkins, and Providence are already piloting the technology to accelerate cancer diagnosis, clinical trial matching, and treatment planning.

Source: https://equity-insider.com/2025/03/21/unlocking-the-trillion-dollar-ai-market-what-investors-need-to-know/   

CONTACT:

Equity Insider

info@equity-insider.com

(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity Insider is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). MIQ has been paid a fee for Avant Technologies Inc. advertising and digital media from the company directly. There may be 3rd parties who may have shares Avant Technologies Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Avant Technologies Inc. which were purchased in the open market. MIQ reserves the right to buy and sell, and will buy and sell shares of Avant Technologies Inc. at any time thereafter without any further notice. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material disseminated by MIQ has been approved by the above mentioned company; this is a paid advertisement, and we own shares of the mentioned company that we will sell, and we also reserve the right to buy shares of the company in the open market, or through other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

Video - https://mma.prnewswire.com/media/2695138/Equity_Insider.mp4

Logo - https://mma.prnewswire.com/media/2644233/5335696/Equity_Insider_Logo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/ai-could-add-461-billion-to-global-healthcareand-these-new-platforms-are-leading-the-charge-302464291.html